The reductions observed in all-cause mortality (49%) and MACE (39%) in high-risk patients compared with statin monotherapy could be practice changing, researchers said.
Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.